Revolution Medicines Inc (NASDAQ: RVMD) on Monday, plunged -6.10% from the previous trading day, before settling in for the closing price of $39.21. Within the past 52 weeks, RVMD’s price has moved between $29.55 and $62.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -38.52% over the past five years. The company achieved an average annual earnings per share of -26.56%. With a float of $161.24 million, this company’s outstanding shares have now reached $185.90 million.
Let’s look at the performance matrix of the company that is accounted for 534 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Revolution Medicines Inc (RVMD) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Revolution Medicines Inc is 13.27%, while institutional ownership is 94.02%. The most recent insider transaction that took place on Jan 21 ’25, was worth 97,443. In this transaction General Counsel of this company sold 2,406 shares at a rate of $40.50, taking the stock ownership to the 39,222 shares. Before that another transaction happened on Jan 21 ’25, when Company’s Officer proposed sale 2,406 for $40.29, making the entire transaction worth $96,938.
Revolution Medicines Inc (RVMD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.88% during the next five years compared to -27.80% drop over the previous five years of trading.
Revolution Medicines Inc (NASDAQ: RVMD) Trading Performance Indicators
Revolution Medicines Inc (RVMD) is currently performing well based on its current performance indicators. A quick ratio of 14.20 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.57, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.91 in one year’s time.
Technical Analysis of Revolution Medicines Inc (RVMD)
Revolution Medicines Inc (NASDAQ: RVMD) saw its 5-day average volume 1.61 million, a positive change from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 29.65%. Additionally, its Average True Range was 1.79.
During the past 100 days, Revolution Medicines Inc’s (RVMD) raw stochastic average was set at 2.65%, which indicates a significant decrease from 10.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.12% in the past 14 days, which was higher than the 44.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.62, while its 200-day Moving Average is $44.63. Nevertheless, the first resistance level for the watch stands at $38.60 in the near term. At $40.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $41.62. If the price goes on to break the first support level at $35.58, it is likely to go to the next support level at $34.34. The third support level lies at $32.56 if the price breaches the second support level.
Revolution Medicines Inc (NASDAQ: RVMD) Key Stats
Market capitalization of the company is 6.85 billion based on 185,913K outstanding shares. Right now, sales total 0 K and income totals -600,090 K. The company made 0 K in profit during its latest quarter, and -194,570 K in sales during its previous quarter.
